Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients

Drug Side Effect Clinical Trial

Official title:
A Phase 2, Randomized, Unicentric Clinical Trial With Dose Scaling for Safety, Tolerability and Efficacy Assessment of 18-Methoxycoronaridine Administered to Cutaneous Leishmaniasis Patients

Status Not yet recruiting

Clinical Trial Summary

It is a randomized phase II clinical study, unicentre aimed to evaluate the tolerability, safety and efficacy of 18-Methoxyoronaridine as a candidate of tegumentary leishmaniasis treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Drug Side Effect
Drug-Related Side Effects and Adverse Reactions
Leishmaniasis
Leishmaniasis, Cutaneous
Leishmaniasis; American, Cutaneous

Clinical Trial Details

NCT number	NCT03084952
Study type	Interventional
Source	Infan Industria Quimica Farmaceutica Nacional
Contact	Jan Carlo Delorenzi, PhD
Phone	+55(11)989780869
Email	jancarlo@hebron.com.br
Status	Not yet recruiting
Phase	Phase 2
Start date	May 2021
Completion date	July 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04659343` - TDM for Optimized Outcome in Patients With mRCC.
Recruiting	`NCT05376943` - Possible Differences in HCC Course Depending on DAA Treatment
Completed	`NCT05144295` - Lubiprostone for Functional Constipation in the Under 18 Years Patients	Phase 3
Enrolling by invitation	`NCT04747678` - Adverse Effects of Ivermectin Used in Egypt During COVID-19